Does bisphosphonate-based anti-osteoporosis medication affect osteoporotic spinal fracture healing?

Ha, Kee-Yong; Park, K.-S.; Kim, S.-I.; Kim, Y.-H.

doi:10.1007/s00198-015-3243-6

Cited by 29 publications

(23 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies demonstrated that the anti-osteoporosis effect could last as long as 1 year after arthroplasty. [ 23 ] In our study, dual-energy X-ray device was used to recognize the periprosthetic Gruen zones automatically, and calculated the BMD at 6 months for patients with, or without oral risedronate after THA. Recently, the positive effect of oral risedronate in THA remains controversial.…”

Section: Discussionmentioning

confidence: 99%

Effect of risedronate on femoral periprosthetic bone loss following total hip replacement

Ren

Wang

2018

Medicine

View full text Add to dashboard Cite

Background:Recent study has reported that risedronate was effective in reducing periprosthesis bone loss after total hip arthroplasty (THA). The meta-analysis was performed to compare the clinical outcomes of THA with oral risedronate versus placebo.Methods:Electronic databases: PubMed (1950–March 2018), EMBASE (1974–March 2018), the Cochrane Central Register of Controlled Trials, Web of Science (1950–March 2018) were systematically searched. Two authors independently graded the methodological quality of each eligible study using the Cochrane Collaboration tool and extracted relevant data. Statistical heterogeneity among the trials were evaluated with chi-square and I-square tests. This meta-analysis was performed using STATA 14.0.Results:A total of 4 randomized controlled trials (RCTs) published between 2006 and 2015 were included in our study. The meta-analysis demonstrated that risedronate was associated with a significantly reduction of periprosthetic bone mineral density after THA. No increased postoperative complications were observed.Conclusion:Oral risedronate might reduce the periprosthetic bone resorption after cementless THA. Additionally, no severe adverse effects were observed. High-quality RCTs with large sample size were still required.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of risedronate on femoral periprosthetic bone loss following total hip replacement

Ren

Wang

2018

Medicine

View full text Add to dashboard Cite

show abstract

“…Because of the small differences in healing time (<1 week), this difference was not considered clinically relevant. In patients with osteoporotic spinal fractures, Ha et al25) recommended suspension of BP use as intervertebral cleft signs on radiographs was more common in patients with a history of BP use, although there were no differences in clinical outcomes. However, regarding intertrochanteric fractures, no study has reported the effects of BPs on patients previously treated with BPs.…”

Section: Discussionmentioning

confidence: 99%

Effect of Preoperative Bisphosphonate Treatment on Fracture Healing after Internal Fixation Treatment of Intertrochanteric Femoral Fractures

Lim

Kim

et al. 2019

Hip & Pelvis

View full text Add to dashboard Cite

Purpose There are concerns that administration of bisphosphonate (BP) can substantially suppress bone turnover, potentially interfering with fracture healing. We investigated the effects of preoperative BP administration before internal fixation of intertrochanteric femoral fractures using fracture healing and clinical outcomes. Materials and Methods We retrospectively analyzed data from 130 patients who underwent internal fixation for osteoporotic intertrochanteric femoral fractures between March 2012 and July 2016. Patients previously treated with BPs for at least 3 months (BP group; n=29) were compared with the remaining patients (BP-naïve group; n=101). Radiographs were used to assess and compare fracture healing 3 months and 1 year postsurgery. The primary clinical outcome measure assessed was change in Koval score. Results Fracture union at 3 months after surgery was verified in 72.4% of patients (21/29) in the BP group and 90.1% of patients (91/101) in the BP-naïve group ( P =0.027). Fracture union at 1 year postsurgery (BP group, 93.1% [27/29] vs. BP-naïve group, 97.0% [98/101], P =0.310) and change in Koval score (1.1 vs. 1.0, P =0.694) were not significantly different between the groups. Multivariable logistic regression analysis revealed that a history of BP administration was associated with an increased risk of delayed union at 3 months postsurgery ( P =0.014). Conclusion Preoperative administration of BP was associated with a decreased fracture healing rate 3 months after internal fixation, compared with BP-naïve patients. Therefore, patients previously treated with a BP should be carefully allowed to wean off walking aids and transition to full weight-bearing in the early postoperative period.

show abstract

“…For instance, bisphosphonates, a major type of anti-osteoporosis medication used in the clinic, have negative effects of excessive suppression of physiological bone turnover, which results in inhibition of the bone remodeling process and impair of fracture healing (31). Certain studies even suggest that suspension of bisphosphonate use should be considered during the fracture healing period (32,33). As an alternative treatment for osteoporosis and numerous other diseases, the therapeutic effects of natural products derived from plants have become an attractive research topic (34,35).…”

Section: Discussionmentioning

confidence: 99%

Combination therapy with BMP‑2 and psoralen enhances fracture healing in ovariectomized mice

Huang

et al. 2018

Exp Ther Med

View full text Add to dashboard Cite

The advantages of combining local delivery of bone morphogenetic protein (BMP)-2 with systemic or local anti-osteoporosis treatments have also been studied for enhancing osteoporotic fracture healing. The aim of the present study was to evaluate the effect of combination therapy with BMP-2 and psoralen on fracture repair in ovariectomized mice. At 6 weeks after bilateral ovariectomy, mice (n=30) underwent unilateral transverse osteotomy on the femur and were divided into 3 groups. In the model group (n=10), animals were implanted with an absorbable collagen sponge (ACS) alone and administered physiological saline intragastrically (i.g.). In the recombinant human (rh)BMP-2 group (n=10), animals were implanted with an ACS loaded with 2.5 µg rhBMP-2 and administered physiological saline i.g. In the psoralen + rhBMP-2 group (n=10) animals were implanted with an ACS loaded with 2.5 µg rhBMP-2 and administered psoralen i.g. The mice were euthanized after 21 days and their fractured femurs were assessed by micro computed tomography, histological analysis and biomechanical testing. Furthermore, the serum of the animals was analyzed. Psoralen + rhBMP-2 exerted more beneficial effects on callus consolidation and biomechanical strength. In addition, increased bone-specific alkaline phosphatase levels and decreased C-terminal telopeptide of type-1 collagen were observed in the Psoralen + rhBMP-2 group. However, no difference in estrogen levels was detected between the groups. In conclusion, the present study demonstrated that in ovariectomized mice, combination of locally delivered BMP-2 and systemically administered psoralen improved bone healing compared with BMP-2 alone.

show abstract

Does bisphosphonate-based anti-osteoporosis medication affect osteoporotic spinal fracture healing?

Cited by 29 publications

References 22 publications

Effect of risedronate on femoral periprosthetic bone loss following total hip replacement

Effect of risedronate on femoral periprosthetic bone loss following total hip replacement

Effect of Preoperative Bisphosphonate Treatment on Fracture Healing after Internal Fixation Treatment of Intertrochanteric Femoral Fractures

Combination therapy with BMP‑2 and psoralen enhances fracture healing in ovariectomized mice

Contact Info

Product

Resources

About